Ovid Therapeutics Inc (OVID) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has a cash flow conversion efficiency ratio of -0.288x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.87 Million) by net assets ($44.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ovid Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Ovid Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ovid Therapeutics Inc (OVID) financial obligations for a breakdown of total debt and financial obligations.
Ovid Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovid Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fima Corporation Bhd
KLSE:3107
|
0.091x |
|
Tai Tung Communication Co Ltd
TW:8011
|
0.049x |
|
eGalax_eMPIA Technology
TWO:3556
|
0.066x |
|
Han Shin Mach
KO:011700
|
0.001x |
|
Ching Feng Home Fashions Co Ltd
TW:9935
|
-0.012x |
|
Simpac
KO:009160
|
0.039x |
|
Hispanotels Inversiones SOCIMI SA
MC:YHSP
|
0.092x |
|
FCW Holdings Bhd
KLSE:2755
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Ovid Therapeutics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see OVID market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.23 Million | $-55.96 Million | -0.820x | -57.29% |
| 2023-12-31 | $87.80 Million | $-45.78 Million | -0.521x | -24.89% |
| 2022-12-31 | $132.27 Million | $-55.23 Million | -0.418x | -163.27% |
| 2021-12-31 | $179.75 Million | $118.61 Million | 0.660x | +155.82% |
| 2020-12-31 | $43.63 Million | $-51.58 Million | -1.182x | -62.04% |
| 2019-12-31 | $70.02 Million | $-51.09 Million | -0.730x | +37.85% |
| 2018-12-31 | $38.81 Million | $-45.56 Million | -1.174x | -211.27% |
| 2017-12-31 | $83.44 Million | $-31.47 Million | -0.377x | -4.44% |
| 2016-12-31 | $49.29 Million | $-17.80 Million | -0.361x | -348.12% |
| 2015-12-31 | $68.07 Million | $-5.49 Million | -0.081x | -46.14% |
| 2014-12-31 | $4.74 Million | $-261.28K | -0.055x | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more